Pfizer Inc (($PFE)) announced an update on their ongoing clinical study. Pfizer Inc. is conducting a Phase 2B clinical study titled ‘A Phase 2B ...

If over-the-counter antihistamines aren’t effective for you, your doctor may recommend H2 blockers, steroids, biologics, or ...

All the hairs have disappeared from a three-inch long patch on my left arm. The bare patch is half the width of my arm and extends just onto the back of my left hand.

Discover how exercise-induced urticaria can turn your workout into a challenge, affecting those who love to run.

“At 36 weeks, I started feeling itchy hands and feet. I lotioned, ignored it, but it kept getting worse. I kept thinking of ...

A runner was forced to quit the sport due to a rare condition that means she’s allergic to water. Erin Cassidy first started ...

The patient has a rash on her cheeks and nose with sparing of the nasolabial folds, in addition to involvement of the dorsal ...

The FDA has approved oral remibrutinib as the first BTK inhibitor for chronic spontaneous urticaria in adults not responding to antihistamines. Rhapsido is a pill taken twice daily and does not ...

Novartis has secured FDA approval for its BTK inhibitor remibrutinib (Rhapsido) for the treatment of chronic spontaneous urticaria. Remibrutinib is the sixth BTK inhibitor to market in the US, and the ...

"Medical Journeys" is a set of clinical resources reviewed by doctors, meant for physicians and other healthcare professionals as well as the patients they serve. Each episode of this journey through ...

Basel: Novartis has announced that Rhapsido (remibrutinib) has received US Food and Drug Administration (FDA) approval as an oral treatment for adult patients with chronic spontaneous urticaria (CSU) ...

"What I Wish I'd Known About Preeclampsia": A Patient's Experience, a Doctor's Thoughts "What I Wish I'd Known About Cataract Surgery": A Doctor Details What Patients ...